Outpost Bio

Outpost Bio, based in the US, harnesses machine learning and microbiology to drive innovations in personalized medicine, focusing on microbial interactions to enhance human health outcomes. Founded in 2025 and headquartered in Boston, US, Outpost Bio specializes in developing computational models and datasets that decode microbial interactions influencing health. The company raised USD 3. 5 mn in a pre-seed funding round on March 2, 2026, co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC and Defined Capital.

There are no known pivots or changes in business operations yet. Outpost Bio specializes in the intersection of microbiology and artificial intelligence to develop innovative solutions aimed at enhancing personalized and predictive medicine. Their core product offerings focus on creating computational models and datasets that decode microbial interactions influencing human health. By leveraging advanced machine learning techniques alongside novel wet lab science, Outpost Bio aims to generate insights that facilitate interventions impacting the human microbiome.

These products are primarily designed for use by researchers and healthcare providers in the fields of precision medicine and biotechnology, with an emphasis on collaboration within the scientific community. Outpost Bio's solutions are targeted at various geographical markets, including North America and Europe, serving academic institutions, healthcare organizations, and industry partners engaged in microbiome research and applications. Outpost Bio's revenue streams are primarily derived from partnerships and collaborations with research institutions, healthcare providers, and biotech companies. The company operates on a model that includes both contractual agreements for the provision of data insights and potential subscription-based services for ongoing access to their proprietary models and datasets.

Transactions typically involve tailored agreements where clients gain access to Outpost Bio's foundational datasets, which are essential for their research and development efforts in microbiome-related interventions. These partnerships may encompass licensing deals, collaborations for pre/post-intervention studies, and shared insights that enhance the understanding of microbiome dynamics. Specific pricing structures for these products and services are determined based on the nature and scope of the partnerships established with clients. In March 2026, Outpost Bio raised USD 3.

5 mn in pre-seed funding, co-led by new investors Merantix Capital and Seedcamp, with participation from OpenSeed VC and Defined Capital. This funding will be utilized to build a comprehensive dataset and models to analyze human microbial communities' interactions with drugs and chemical inputs. The company plans to expand its offerings into new geographical markets in North America and Europe, focusing on enhancing its product range to include new computational models designed for specific health interventions.